ReviewBiochimica et biophysica acta2015
The Wnts of change: How Wnts regulate phenotype switching in melanoma.
Review in Biochimica et biophysica acta, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- A MAFG~MITF complex drives melanoma phenotype switching and progression.Nature communications · 2026Article
- Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression.Molecular cancer · 2025Article
- Identification of biomarkers related to the progression of cutaneous melanoma and construction of survival prognosis model.Discover oncology · 2025Article
- Targeting Neuronal Nitric Oxide Synthase (nNOS) as a Novel Approach to Enhancing the Anti-Melanoma Activity of Immune Checkpoint Inhibitors.Pharmaceutics · 2025Article
- Double-sided niche regulation in skin stem cell and cancer: mechanisms and clinical applications.Molecular cancer · 2025Review
- Deciphering pre-existing and induced 3D genome architecture changes involved in constricted melanoma migration.iScience · 2025Article
- WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells.Cancer chemotherapy and pharmacology · 2025Article
- Stochastic modeling of single-cell gene expression adaptation reveals non-genomic contribution to evolution of tumor subclones.Cell systems · 2025Article
- The small MAF transcription factor MAFG co-opts MITF to promote melanoma progression.bioRxiv : the preprint server for biology · 2024Article
- Stochastic modelling of single-cell gene expression adaptation reveals non-genomic contribution to evolution of tumor subclones.bioRxiv : the preprint server for biology · 2024Article
- Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation.JCI insight · 2024Article
- Exploring the relationship between total serum calcium and melanoma development: a cross-sectional study.Frontiers in nutrition · 2024Article
- Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance.International journal of molecular sciences · 2023Review
- Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer.Cellular and molecular life sciences : CMLS · 2023Review
- Article
- Article
- Cancer Stem Cells: From an Insight into the Basics to Recent Advances and Therapeutic Targeting.Stem cells international · 2022Review
- EVI/WLS function is regulated by ubiquitylation and is linked to ER-associated degradation by ERLIN2.Journal of cell science · 2021Article
- Reduced WNT5A signaling in melanoma cells favors an amoeboid mode of invasion.Molecular oncology · 2021Article
- PLEKHA4 Promotes Wnt/β-Catenin Signaling-Mediated GCancer research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The outgrowth of metastatic and therapy-resistant subpopulations in cancer remains a critical barrier for the successful treatment of this disease. In melanoma, invasion and proliferation are uncoupled, such that highly proliferative melanoma cells are less likely to be invasive, and vice versa. The transition between each state is likely a dynamic rather than a static, permanent change. This is referred to as "phenotype switching". Wnt signaling pathways drive phenotypic changes and promote therapy resistance in melanoma, as well as play roles in the modulation of the immune microenvironment. Three Wnt signaling pathways play a role in melanoma progression, canonical (β-catenin dependent), polar cell polarity (PCP), and the Wnt/Ca²⁺ pathway. Here we summarize phenotype plasticity and its role in therapy resistance and immune evasion. Targeting the Wnt signaling pathways may be an effective way to overcome tumor plasticity in melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.